Uveitis Treatment Trials—A Cross-study Perspective

Cunningham, Emmett T.; Goldstein, Debra A.; Zierhut, Manfred

doi:10.3109/09273948.2012.661297

Cited by 5 publications

(3 citation statements)

References 42 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 5 9 ] However, <76% of cases can be fully controlled using IMT agents, and only 36%–61% of cases can be successfully controlled without systemic corticosteroids despite using these IMT medications for more than 1 year. [ 10 ]…”

Section: Introductionmentioning

confidence: 99%

Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan

Hwang

Tsai

et al. 2018

Taiwan J Ophthalmol

View full text Add to dashboard Cite

Noninfectious uveitis is a sight-threatening disease with an autoimmune or autoinflammatory basis. Systemic treatment is required if intraocular inflammation threatens a patient's vision or cannot be controlled locally and when it is associated with systemic rheumatic diseases. Corticosteroids and immunomodulatory chemotherapy are the conventional initial treatments. However, the various side effects of these therapies increase the burden on patients, not only physically but also mentally. Moreover, uncontrolled inflammation and poor visual outcomes have sometimes been recorded despite the combination of these medications or their high dosage. Antitumor necrosis factor-alpha (anti-TNF-α) and other biologic agents have been widely used to treat rheumatic diseases for >15 years. Randomized controlled clinical trials have demonstrated that anti-TNF-α can reduce and delay episodes of intraocular inflammation not only in patients with active uveitis but also in corticosteroid-dependent patients with inactive uveitis. The Taiwan Food and Drug Administration approved the use of adalimumab, an anti-TNF-α agent, for treating nonanterior noninfectious uveitis (NANIU) in 2017. This report provides a recommendation and a proposed stepladder approach for using anti-TNF-α agents to treat NANIU in Taiwan.

show abstract

Section: Introductionmentioning

confidence: 99%

Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan

Hwang

Tsai

et al. 2018

Taiwan J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…[14][15][16] Although employed in the current study, the popularity of CSA as a corticosteroid-sparing immunosuppressive agent in patients with uveitis has decreased over time 17,18 for reasons related to both tolerability and efficacy. 19,20 Silpa-archa et al 8 retrospectively analyzed 144 consecutive patients with typical BSCR and at least 12 months of follow up seen at a tertiary referral center in Boston, Massachusetts, USA, between 2005 and 2014. For comparison, subjects were categorized as early (< 50 years of age; n = 68) vs late-onset (≥ 50 years of age; n = 76) BSCR.…”

mentioning

confidence: 99%

Birdshot Chorioretinopathy

Cunningham

Levinson

Denniston

et al. 2017

Ocular Immunology and Inflammation

Self Cite

View full text Add to dashboard Cite

“…9 Of note, Deuter and colleagues have reported a drug-free remission rate of nearly 90% in patients with Behçet's disease whose uveitis was treated and controlled with interferon-a, 10 an agent used infrequently outside of Europe. 11,12 Miserocchi and associates describe their experience using golimumab, a humanized, subcutaneously administered anti-TNF-a agent engineered from infliximab, in 17 patients with severe, refractory uveitis, including 13 with JIA and 4 with HLA-B27-associated uveitis. 5 Eight patients (47.1%) had anterior uveitis and nine (52.9%) panuveitis.…”

mentioning

confidence: 99%